Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates

Published: Apr 23, 2024 By Nick Paul Taylor

Incyte_iStock, Bo Shen

Pictured: Incyte building in Wilmington, Delaware/iStock, Bo Shen

Incyte announced Tuesday that it is buying Escient Pharmaceuticals for $750 million to gain control of a pipeline led…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks